Genetic Testing in Czechia

A genetic test detecting inherited thrombophilia (clotting-risk) mutations — relevant before pregnancy, hormone therapy or surgery, or with a family history of clots. Self-pay, no referral, results delivered electronically.

A genetic test that screens for hereditary mutations associated with an increased predisposition to blood clots (thrombophilia). It is frequently chosen by people considering or using hormonal contraception, those with a family history of clotting, or anyone wanting to understand their inherited clotting risk. Self-pay with no referral — book and pay online, attend a collection point, receive a genetic results report.

Initial consultation with genetic specialist to discuss testing options.

This genetic test analyses inherited variants associated with an increased tendency to abnormal blood clotting (thrombophilia). The base panel covers the two most clinically important variants — Factor V Leiden and the prothrombin G20210A mutation — and an extended panel adds the MTHFR variant. The test is performed from a blood sample and is often requested before hormonal therapy, in pregnancy planning, or after a personal or family history of thrombosis.

Consultation with results interpretation and diagnosis discussion.

A celiac-disease genetic test through LABSHOP analysing HLA-DQ predisposition markers to assess genetic risk of celiac disease. Order online and collect the sample at a SPADIA point in Prague.

This non-invasive test determines the sex of the fetus by detecting Y-chromosome (SRY gene) DNA fragments in a maternal blood sample. It requires only a routine blood draw and can be performed from early in pregnancy, giving expectant parents an early and reliable answer without any invasive procedure. The same SRY detection method is also offered as a standalone test, for example for sport eligibility verification.

For pregnancies undergoing invasive sampling (amniocentesis or chorionic villus sampling), the laboratory provides diagnostic chromosomal analysis of the fetal sample. Options range from rapid QF-PCR detection of the most common aneuploidies through to a full fetal karyotype and high-resolution microarray analysis for microdeletion and microduplication syndromes. These are confirmatory diagnostic tests, typically performed after a high-risk screening result or on clinical indication.

Sperm DNA fragmentation test for male fertility assessment.

Evaluation of chromosome aberrations in peripheral blood.

MEDEOR offers the GenePlanet NIPT, a self-pay non-invasive prenatal screening blood test available through its Přerov collection point. From a maternal blood sample it screens for the common chromosomal conditions (such as Down syndrome) and can determine fetal Rh status, with no risk to the pregnancy and no referral needed.

Cytogenetic analysis of chromosomes from blood sample.

A karyotype is a microscope-level analysis of all of a person's chromosomes, prepared by culturing cells from a peripheral blood sample. It detects numerical chromosome abnormalities and larger structural rearrangements such as translocations, deletions, and duplications. The test is commonly requested in the work-up of infertility, recurrent pregnancy loss, developmental concerns, or a family history of chromosomal conditions. An expedited STAT option is available when a faster result is needed.

The laboratory provides DNA paternity and kinship testing using standard STR profiling of buccal swab or blood samples. A personal (informational) test answers the question privately for the participants, while the expert test follows a documented chain-of-custody procedure so the result is admissible as evidence in court and official proceedings. Both establish biological relationship with very high statistical certainty.

This genetic test screens for 68 of the most common mutations in the CFTR gene, the gene responsible for cystic fibrosis. Cystic fibrosis is one of the most common inherited recessive conditions, and carrier screening identifies whether a person carries a CFTR mutation. It is commonly requested by couples planning a pregnancy, by people with a family history of cystic fibrosis, and in the investigation of certain fertility problems.

Measure biological age through telomere analysis.

CAPART (Czech Accurate Prenatal Aneuploidy Rapid Test) is a non-invasive prenatal test that analyses fetal DNA circulating in a maternal blood sample to screen for the most common chromosomal trisomies, including trisomy 21 (Down syndrome), 18 and 13. Introduced by the laboratory in 2026, it requires only a routine blood draw from the mother and carries none of the miscarriage risk associated with invasive sampling. Expanded variants add sex chromosome assessment and broader aneuploidy panels. The test is suitable from early in the second trimester and is offered to self-paying patients who want reassurance beyond standard ultrasound screening.

Non-invasive prenatal genetic screening test from maternal blood.

Genetic testing for hereditary breast and ovarian cancer predisposition.

Galen Clinic's oncogenetic testing analyses genes linked to an increased risk of the most common hereditary cancers, including the high-risk BRCA1 and BRCA2 genes. The panel covers genes associated with elevated risk of breast, ovarian, prostate, colorectal, pancreatic, kidney, skin and other cancers. The test is performed from a simple blood sample taken during a standard clinic visit and sent to a specialised genetics laboratory, with results typically available within about a month. Because a result can carry significant personal and family implications, testing is always preceded by a physician consultation to choose the right test and explain what the results mean; any clinically significant finding is interpreted together with a clinical geneticist. The aim is not to diagnose existing disease but to inform a personalised, better-targeted prevention and monitoring plan.

EliteMedical offers DNA health testing that analyses 47 genes organised across eight preventive health categories: oxidative stress and antioxidant capacity, detoxification ability, inflammation predisposition, methylation and gene expression regulation, lipid and cholesterol metabolism, bone health, insulin sensitivity, and vitamin metabolism (vitamins A, D, C, and B12). The test is performed from a simple saliva or blood sample and results are interpreted in Czech by an EliteMedical physician or health specialist, with personalised recommendations covering diet, supplementation, and lifestyle adjustments based on the patient's specific genetic variants. Unlike diagnostic genetic tests for monogenic diseases, this test focuses on polygenic health trait variants — the kind that influence susceptibility and response to lifestyle interventions. It is particularly valuable for people with a strong family history of chronic disease (cardiovascular, metabolic, bone, or inflammatory conditions) who want to understand their personal risk landscape before symptoms emerge.

Preventbox is an expanded genetic carrier screening package that analyses a person's DNA for predisposition to 111 inherited conditions in a single test. It is aimed at people planning a family or wanting a broad preventive overview of their genetic carrier status, going well beyond single-gene tests by screening many recessive conditions at once.

5P Medicine's predictive genomics service analyses single nucleotide polymorphisms (SNPs) to identify inherited predispositions to civilisation diseases — cardiovascular risk, metabolic disorders, certain cancers and neurodegenerative conditions — before any symptoms appear. DNA is processed in partnership with Laboratoires REUNIS in Luxembourg, one of Europe's leading specialist genomics laboratories. MUDr. Hora, who performed the first genomic examination in the Plzeň region back in 2009, interprets results in a detailed personalised report and translates genetic risk factors into actionable lifestyle, diet and supplementation recommendations. The key insight: predisposition is not destiny — environmental and lifestyle factors can modulate gene expression significantly.